Ads
related to: renal cell carcinoma treatment
Search results
Drug targeting clear cell renal cell carcinoma shows promising approach
Newswise· 3 days agoApril 23, 2024 – In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center,...
Merck (MRK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 10 hours agoOutside the U.S., KEYTRUDA growth was driven by continued uptake in earlier-stage cancers, including high-risk, early stage, triple-negative breast...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 1 day agoOverall, 27.3% responded to the treatment. A total of 63.6% of patients had their disease under...
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 1 day agoThe NDA is supported by results from JUPITER-02, a randomized, double-blind, placebo-controlled, multinational...
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
ThePress.net· 1 day agoSAN FRANCISCO and SUZHOU, China, April 24, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the
Cancer drug trial provides lessons for future
Medical Xpress· 12 hours agoA cancer drug was found to be ineffective in preventing recurrence of kidney cancer in patients who recently underwent tumor removal surgery, according to a clinical trial published in the Journal ...
Merck highlights progress on HIV, hypertension, cervical cancer drugs
WFMZ Eastern Pennsylvania and Western New Jersey· 12 hours agoMerck, with multiple facilities in eastern Pennsylvania and New Jersey, also delivered good news...
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Zacks via Yahoo Finance· 12 hours agoBiotechnologies and Icosavax during the quarter, enabling management to accelerate its cell therapy...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 4 days agoKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 2 days agoNew York, USA, April 24, 2024 (GLOBE NEWSWIRE) -- HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the growth of the HDAC inhibitors market is expected
Ads
related to: renal cell carcinoma treatment
